clinical trial · NCT04153149
HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Transthyretin Amyloidosis (ATTR) With CardiomyopathyVutrisiranSterile Normal Saline (0.9% NaCl)
brief summary
This study will evaluate the efficacy and safety of vutrisiran 25 mg administered subcutaneously (SC) once every 3 months (q3M) compared to placebo in participants with ATTR amyloidosis with cardiomyopathy.
started
Nov 26, 2019
primary completion
May 8, 2024
completion
Dec 2, 2026
last updated
Jan 12, 2026
official title
HELIOS-B: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol